Robot-assisted Thoraco-laparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy

Esophageal Cancer Clinical Trial

— ROBOT  

Official title:

Robot-assisted Minimally Invasive Thoraco-laparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy for Resectable Esophageal Cancer. The ROBOT-trial: a Monocenter Randomized Controlled Trial.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01544790
• Other study ID #: NL35048.041.11
• Secondary ID: 11141
• Status: Completed
• Phase: Phase 3
• Start date: April 2012
• Est. completion date: August 2016

Study information

• Verified date: March 2020
• Source: UMC Utrecht
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is the first randomized controlled trial designed to compare robot-assisted minimally invasive thoraco-laparoscopic esophagectomy with open transthoracic esophagectomy as surgical treatment for resectable esophageal cancer.

If our hypothesis is proved correct, robot-assisted minimally invasive thoraco-laparoscopic esophagectomy will result in a lower percentage of postoperative complications, lower blood loss, shorter hospital stay, but with at least similar oncologic outcomes and better postoperative quality of life compared with the open transthoracic esophagectomy (current standard).

Description:

Rationale: As stated in the 2010 revised Dutch esophageal carcinoma guidelines, the golden standard for surgical treatment of esophageal carcinoma is open transthoracic esophagectomy. Recent evidence suggests that robot-assisted thoraco-laparoscopic esophagectomy using the Da Vinci ® robot can provide an extensive resection, with possibly better or at least equal radical (R0) resection rates and an equal number of dissected lymph nodes. This is accompanied with markedly reduced blood loss and reduction of overall complications with shorter intensive care unit (ICU) and hospital stay. Therefore, the robot-assisted thoraco-laparoscopic esophagectomy is now at a stage that it should be compared to the current standard of care in a randomized controlled trial.

Objective: Evaluate the benefits, risks and costs of robot-assisted thoraco-laparoscopic esophagectomy as an alternative to open transthoracic esophagectomy as treatment for esophageal cancer.

Study design: Randomized controlled parallel-group superiority trial Study population:

Patients (age ≥ 18 and ≤ 75 jaar) with histologically proven surgically resectable (cT1-4a, N0-3, M0) squamous cell carcinoma, adenocarcinoma or undifferentiated esophageal carcinoma of the intrathoracic esophagus with European Clinical Oncology Group (ECOG) status 0, 1 or 2.

Intervention: 112 patients will be randomly allocated to either A) robot-assisted thoraco-laparoscopic esophagectomy (n=56) or B) open transthoracic esophagectomy (n=56).

Patients will receive the following interventions:

Group A. Robot-assisted thoraco-laparoscopic esophagectomy, with gastric conduit formation.

Group B. Open transthoracic esophagectomy, with gastric conduit formation.

Main study parameters/endpoints: Primary outcome is the percentage of overall complications (Grade 2 and higher) as stated by the modified Clavien-Dindo classification (MCDC).

Secondary outcomes are individual components of the primary endpoint (major and minor complications), (in hospital) mortality within 30 and 60 days, R0 resections, operation related events, postoperative recovery, oncologic outcomes, cost-effectiveness and quality of life.

Follow-up: 60 months after randomization

Recruitment information / eligibility

• Status: Completed
• Enrollment: 112
• Est. completion date: August 2016
• Est. primary completion date: August 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Histologically proven squamous cell carcinoma, adenocarcinoma or undifferentiated carcinoma of the intrathoracic esophagus.

• Surgical resectable (T1-4a, N0-3, M0)

• Age = 18 and = 75 years

• European Clinical Oncology Group (ECOG) performance status 0,1 or 2

• Written informed consent

Exclusion Criteria:

• Carcinoma of the cervical esophagus

• Carcinoma of the gastro-esophageal junction (GEJ) with major tumor in the gastric cardia (Siewert III)

• Prior thoracic surgery at the right hemithorax or thorax trauma (rationale: these patients will undergo open resection)

Related Conditions & MeSH terms

• Esophageal Cancer
• Esophageal Carcinoma
• Esophageal Neoplasms

Intervention

Procedure:
• Esophagectomy
In this monocenter prospective randomized controlled trial, we compare robot-assisted minimally invasive esophagectomy with conventional open transthoracic esophagectomy.

Locations

Country	Name	City	State
Netherlands	UMC Utrecht	Utrecht

Sponsors (1)

Lead Sponsor	Collaborator
UMC Utrecht

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Postoperative complications modified Clavien-Dindo classification (MCDC) grade 2 and higher	The primary outcome of this study is the percentage of overall complications (Grade 2 and higher) as stated by the modified Clavien-Dindo classification of surgical complications (MCDC)	Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Secondary	Individual components of the primary endpoint (major and minor complications)	Major complications (MCDC grade 2-4) Including: myocardial infarction, anastomotic leakage (clinical or radiologic diagnosis), anastomotic stenosis, chylothorax (chylous leakage, presence of chylous in chest tubes or indication start medium chain triglycerides containing tube feeding (Vivonex®), gastric tube necrosis (proven by gastroscopy), pulmonary embolus, deep vein thrombosis, vocal cord palsy or paralysis.; Minor complications (MCDC grade 1) Including: wound infections, pleural effusions, delayed gastric emptying	Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Secondary	(In hospital) Mortality within 30 and 60 days	(In hospital) mortality and mortality within 30 and 60 days will be reported. The cause of death and the results of the autopsy report will be noted.	Participants will be followed for the duration of hospital stay, an expected average of 2 weeks and within 30 days or 60 days
Secondary	R0 resections (%)	The pathological analysis will be finished within 2 weeks.	Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Secondary	Operation related events	Operation time is defined as time from incision until closure (minutes) for both the thoracic and the abdominal phase of the procedure. For the robotic procedure, set up time will be recorded separately. Unexpected events and complications occurring during the operation will be recorded (e.g. massive hemorrhage, perforation of other organs).; Blood loss during operation (ml, per phase). In case of conversion to thoracotomy or laparotomy the reason for conversion has to be explained (absolute numbers/percentage).	Day of surgery, up to 24 hours after surgery.
Secondary	Postoperative recovery	Pain: Type and dose of used analgesics will be noted during the hospital admission period.; Visual Analogue Scale (VAS) for pain will be noted at following times: pre-operatively and the first 10 days after surgery and a fixed periods during follow up (6 weeks, 6 months and yearly post-operatively up to 5 years).; Length of intensive care unit (ICU) - medium care unit (MCU) stay (days). Length of hospital stay (days).	Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Secondary	Oncologic outcomes	2, 3 and 5 year disease free and overall survival	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months after surgery.
Secondary	Quality of life	Questionnaires will be required at following times: SF-36, EORTC QLQ-C30 (Dutch), EORTC OES18 (Dutch) and EQ-5D (Appendix 1 & 2) pre-operative < 5 days and 6 weeks, 6 months and yearly up to 5 years post-operatively.	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months after surgery.
Secondary	Costs (euro)	Direct general costs, due to extra operating room time and extra instruments. Indirect costs, such as reduced ICU or hospital stay.	5 years follow up